MedTrace Logo

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

NCT00677300 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2014-09-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether a combination of raltegravir and darunavir is as effective as standard regimens in the treatment of HIV-infected patients who have not previously used antiretroviral drug (treatment naive)

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir

400mg P.O. (orally) twice daily for 48 weeks

DRUG

Darunavir

800 mg P.O. (orally) once daily

DRUG

Ritonavir

100mg once daily

DRUG

Tenofovir/Emtricitabine

300 mg/200 mg P.O. (orally) once daily

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Tibotec Pharmaceutical Limited

    collaborator INDUSTRY

  • Dallas VA Medical Center

    lead FED

Principal Investigators

  • Roger Bedimo, M.D. · Dallas VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-10-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677300 on ClinicalTrials.gov